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ABSTRACT 
Context Optimal diagnostic and treatment modalities in chronic pancreatitis are controversial due to lack of 
evidence. Objective To evaluate current clinical practice, we conducted a survey with the primary objective to 
evaluate decisions regarding the diagnosis, management and screening in chronic pancreatitis. Design We 
developed a vignette survey. Setting We surveyed Dutch gastroenterologists, internists, gastrointestinal 
surgeons and an international expert panel. Results A total of 110 questionnaires (31% gastroenterologists, 
39% internists and 20% gastrointestinal surgeons) were returned out of the 1,324 sent (response 8.3%). There 
was a wide variation in strategies regarding diagnosis, treatment and screening in chronic pancreatitis. As a 
diagnostic test, serum amylase is used frequently by internists, while gastroenterologists and experts often use 
fecal elastase. Most respondents preferred CT-scanning for diagnosis, while experts preferred transabdominal 
ultrasonography as an initial test. Respondents frequently use pancreatic enzymes for treatment of pain in 
chronic pancreatitis. The majority advised to perform an intervention (endoscopic or surgical) in case of 
morphological changes of the pancreatic duct. Conclusions The results of our survey identify important 
differences between physicians in diagnosis and management of chronic pancreatitis. This is often due to lack of 
evidence and consensus in literature. Certain wide-spread practices are in contrast with available evidence, and 
should be addressed by improved education and adherence to guidelines. 
  
  
INTRODUCTION 
  
There are a number of challenges when it comes to the diagnosis and treatment of 
chronic pancreatitis. The diagnosis of chronic pancreatitis depends on interpretation of a 
variety of diagnostic tests, all of them aimed to detect structural and functional changes 
of the pancreas. Early in the disease course diagnosis is difficult, particularly when 
abdominal pain is the only symptom and the results of imaging tests are unequivocal [1]. 
In order to guide the clinician, several groups have attempted to design classifications 
and scorings systems for chronic pancreatitis [1, 2, 3, 4]. For example, the M-ANNHEIM 
classification formulates criteria for definitive, probably and borderline chronic 
pancreatitis [5]. This classification also has components that allow patients to be 
categorized according to etiology, clinical stage, and severity of chronic pancreatitis. 
Even when the diagnosis is established, a clear treatment protocol for chronic 
pancreatitis is lacking. Common opinion is that the treatment of chronic pancreatitis 
should be guided by the clinical presentation and specific complaints of the patient. A 
major issue is the lack of evidence for treatment paradigms. Nevertheless, several 
recommendations on therapy in chronic pancreatitis have been published [6, 7, 8, 9, 10]. 
In addition two recent guidelines have been published [11, 12]. In 2010 the Italian 
Association for the Study of the Pancreas published an Italian consensus regarding 
diagnosis and treatment in chronic pancreatitis. This consensus appraised the best 
available evidence combined with input from experts [11]. After a consensus meeting 
several statements on the diagnosis and treatment on chronic pancreatitis were made. 
The South African guidelines are based on best practice principles determined by the 
available evidence and the opinions of an expert group [12]. 
All in all, despite guidelines, important controversies concerning the diagnosis and 
treatment of chronic pancreatitis remain. Moreover, adherence to these guidelines is 
unclear. In an effort to revisit the most important issues, we developed a survey to 
evaluate current clinical practice in the Netherlands. The primary objective of this study 
was to evaluate decisions regarding the diagnosis, management and screening in chronic 
pancreatitis. 
  
METHODS 
  
Vignette Survey Design 
  
We developed a vignette survey to evaluate decisions regarding essential aspects of the 
diagnosis and management of chronic pancreatitis aided by representative scenarios in 
chronic pancreatitis. The questionnaire included three clinical chronic pancreatitis cases 
(vignettes), followed by multiple-choice and open questions. The three vignettes were 
designed to evaluate controversies in the diagnosis, treatment and screening of chronic 
pancreatitis. The first clinical vignette assessed the use of diagnostic tests and the 
criteria to diagnose chronic pancreatitis. The second vignette assessed therapeutic 
decision making in chronic pancreatitis, regarding both medical and interventional 
therapies. The third vignette assessed aspects regarding screening and follow-up of 
hereditary pancreatitis. We developed the vignettes in cooperation with chronic 
pancreatitis experts of the Dutch Pancreatitis Study Group (www.pancreatitis.nl) and the 
Scientific Institute for Quality of Healthcare of our institution 
(http://www.iqhealthcare.nl). Each vignette included the patient’s history, physical 
examination and results of relevant additional investigations (e.g., laboratory 
investigation, imaging or other diagnostic tests). This was followed by a number of 
questions pertaining to diagnostic testing, treatment and follow-up decisions. The full 
vignettes are presented in the supplementary file. Furthermore, the questionnaire 
included several questions regarding the clinical experience and the setting in which the 
physician provides care: type of hospital (academic vs. community), the number of 
chronic pancreatitis patients in their practice, and type of interventions performed, if any. 
  
Sampling Frame 
  
Three provider groups mainly involved in care for chronic pancreatitis patients in the 
Netherlands were surveyed: 1) gastroenterologists; 2) specialists internal medicine 
(internists); and 3) gastrointestinal surgeons. Additionally, we established an expert 
panel comprised of seven health professionals and leading researchers in the field of 
chronic pancreatitis as a fourth group (i.e., experts). Members of this panel were non-
Dutch physicians selected on the basis of demonstration of knowledge and competence 
documented by an extensive publication record on chronic pancreatitis. We surveyed all 
gastroenterologists registered as members of the Dutch Association of Specialists for 
Gastroenterology-Hepatology (n=344). We also surveyed all internists registered as 
members of the Netherlands Association of Internal Medicine, working in a non-academic 
hospitals (n=833). Furthermore, we surveyed gastrointestinal surgeons, registered as 
member of the Netherlands Society for Gastrointestinal Surgery (n=422). 
  
Survey Distribution and Follow-up Procedures 
  
A request to participate in the survey was sent to the gastroenterologists and internists 
directly by e-mail, accompanying by a link to an online questionnaire platform. Non-
responders received two reminder e-mails. In the provider group of gastrointestinal 
surgeons, a request for participation was forwarded by the secretary of the Netherlands 
Society for Gastrointestinal Surgery. 
  
STATISTICS 
  
Results of all questions were analyzed separately and presented according to topic. Data 
are presented for the group of gastroenterologists, internists and gastrointestinal 
surgeons together and for the provider groups separately. We discuss differences of 
Dutch physicians and compare them to the strategies of non-Dutch experts. Statistical 
analysis was carried out by using the SPSS 18.0 for Windows. Frequencies of proposed 
diagnostic or treatment strategies for each vignette were calculated and compared 
among the three groups (gastroenterologists, internists, gastrointestinal surgeons) using 
the chi-square test (asymptotic P values). When the expected values in any of the cells 
of a contingency table were below 5, the Fisher’s exact test was used (exact P values). 
We only performed a statistical analysis on diagnostic and therapeutical strategies of the 
gastroenterologists, internists and gastrointestinal surgeons. Statistical significance was 
defined as two-tailed P values less than 0.05. We discussed these outcomes in relation 
with the strategies of the experts. 
  
RESULTS 
  
Sample Characteristics 
  
Table 1 displays the characteristics of the survey respondents. Requests for participation 
were sent to 1,599 physicians. 236 surveys sent to internists and gastroenterologists 
were returned because of incorrect addresses. Some 39 surveys were returned because 
the addressee did not treat chronic pancreatitis patients. One hundred ten physicians of 
the remaining 1,324 requests for participation sent returned their surveys (response 
percentage 8.3%). From the respondents, 34 of the responders were gastroenterologists 
(30.9%), 43 internists (39.1%), 22 gastrointestinal surgeons (20.0%) and 11 (10.0%) 
respondents ‘other’ (e.g., 5 intensivists, 1 nephrologist, and 5 not reported) (Table 1). 
The mean age of respondents was 47 years (range: 33-66 years). The majority of 
physicians provided care in a non-academic hospital (63/105, 60.0%) and had a clinical 
experience of 10-20 years (gastroenterologists 20/33, 60.6%; gastrointestinal surgeons: 
13/22, 59.1%) or more than 20 years (internists 28/43, 65.1%). 
Seventy-three (71.6%) out of 102 respondents provided care for chronic pancreatitis 
patients. Most indicated that they treat chronic pancreatitis patients themselves, and only 
a minority (n=29, 28.4%) referred patients to specialized centers on a regular basis. A 
total of 12 (35.3%) responding gastroenterologists also indicated to perform endoscopic 
ultrasonography (EUS)-guided drainage of pancreatic fluid collections and 16 (47.1%) of 
the gastroenterologists performed endoscopic intervention in chronic pancreatitis 
patients. Fourteen (63.6%) of all responding surgeons indicated that they did operate on 
chronic pancreatitis patients. 
  
  
Table 1. Characteristics of the respondents. 
  Gastroenterologists 
(n=34) 
Internists 
(n=43) 
Gastrointestina  
surgeons (n=22  
  
 
Practice: 
- Academic hospital 
 
3 (8.8%) 
 
0 
 
7 (31.8%) 
 
 
- Non-academic teaching hospital 
- Non-academic non-teaching hospital 
Number of valid responses 
23 (67.6%) 
8 (23.5%) 
34 
24 (55.8%) 
19 (44.2%) 
43 
11 (50.0%) 
4 (18.2%) 
22 
  
 
 
Years in practice: 
- 0-10 years 
- 10-20 years 
- More than 20 years  
Number of valid responses 
 
4 (12.1%) 
20 (60.6%) 
9 (27.3%) 
33 
 
5 (11.6%) 
10 (23.3%) 
28 (65.1%) 
43 
 
1 (4.5%) 
13 (59.1%) 
8 (36.4%) 
22 
 
  
  
  
 
Number of chronic pancreatitis patients seen (yearly): 
- 0-10 
- 10-30 
- More than 30 
Number of valid responses 
 
17 (51.5%) 
14 (42.4%) 
2 (6.1%) 
33 
 
37 (88.1%) 
4 (9.5%) 
1 (2.4%) 
42 
 
15 (68.2%) 
4 (18.2%) 
3 (13.6%) 
22 
 
  
 
 
 
a Other: 5 intensivists, 1 nephrologist, and 5 not reported 
  
  
Diagnosis 
  
We presented a typical case of chronic pancreatitis with continuous abdominal pain and 
frequent exacerbations and asked which laboratory test is an important part of the 
diagnostics. The most common test used was fecal elastase (54/110, 49.1%). Fecal 
elastase was most often chosen by gastroenterologists (25/34, 73.5%) and by experts in 
71.4% (5/7). On the other hand, amylase was considered as a diagnostic tool in chronic 
pancreatitis by 42.9% (3/7) of experts, compared to 38.2% (13/34) of the 
gastroenterologists, 27.3% (6/22) of the gastrointestinal surgeons and 72.1% (31/43) of 
the internists (Figure 1). When subsequently asked which imaging modality was used 
first at suspicion of chronic pancreatitis, only a minority (22/91, 24.2%) of all 
respondents considered transabdominal ultrasonography as useful in diagnosing chronic 
pancreatitis, compared to 71.4% (5/7) experts (Figure 2). The majority of the 
respondents (63/91, 69.2%) indicated they used CT instead as the confirmatory test, 
whereas only 2 out of 7 (28.6%) experts would perform a CT in this case. 
  
  
 Figure 1. Diagnostic strategies are questioned in a clinical vignette. In 
this case, we ask the physicians which laboratory test plays an 
important part of their diagnostics. 
  
  
 
Figure 2. In a clinical vignette, the respondents were asked which 
radiological modality they prefer first diagnostic tool in considering 
chronic pancreatitis in a patient. 
TUS: transabdominal ultrasonography 
EUS: endoscopic ultrasonography 
  
  
Regarding the criteria for establishing chronic pancreatitis, we noted large differences 
between the different categories of respondents (Table 2). Some 73.8% (62/84) of the 
respondents and all 7 experts diagnosed chronic pancreatitis in case of chronic abdominal 
pain and calcifications on a plain abdominal X-ray. In case of relapsing pseudocysts 
78.8% (67/85) of all respondents regarded this as indicative for chronic pancreatitis 
compared to 71.4% (5/7) experts. Five out of 12 (41.7%) of the gastrointestinal 
surgeons and 32.4% (12/37) of the internists diagnosed chronic pancreatitis in case of 
chronic abdominal pain and elevated amylase, compared to only 6.7% (2/30) of the 
gastroenterologists (P=0.009). 
Regarding etiology, 46.1% (41/89) of the respondents considered alcohol as a cause of 
chronic pancreatitis at consumption of 4 or more standard drinks/day for men and 3 or 
more standard drinks/day for women during more than 6 months (by considering 12 g 
ethanol in each drink). 
  
  
Table 2. When do you diagnose chronic pancreatitis? 
  Overall 
(n=110) a 
Gastroenterologists 
(n=34) 
Internists 
(n=43) 
Gastrointestinal 
surgeons (n=22) 
    
 
Chronic "typical" abdominal pain without 
alternative diagnosis 
6/80 
(7.5%) 
1/30 
(3.3%) 
3/37 
(8.1%) 
1/11 
(9.1%) 
  
 
Chronic abdominal pain and elevated 
amylase 
20/81 
(24.7%) 
2/30 
(6.7%) 
12/37 
(32.4%) 
5/12 
(41.7%) 
  
 
Chronic abdominal pain and calcifications 
on abdominal X-ray 
62/84 
(73.8%) 
25/31 
(80.6%) 
29/39 
(74.4%) 
6/12 
(50.0%) 
  
 
Chronic abdominal pain and first 
complaints of steatorrhea  
33/79 
(41.8%) 
12/30 
(40.0%) 
15/36 
(41.7%) 
5/11 
(45.5%) 
  
 
Steatorrhea, improving with pancreatic 
enzyme supplementation 
47/81 
(58.0%) 
17/30 
(56.7%) 
22/37 
(59.5%) 
7/12 
(58.3%) 
  
 
Decreased fecal elastase 32/79 
(40.5%) 
14/30 
(46.7%) 
12/36 
(33.3%) 
4/11 
(36.4%) 
  
Relapsing pseudocysts 67/85 
(78.8%) 
22/31 
(71.0%) 
33/40 
(82.5%) 
11/12 
(91.7%) 
  
 
Dilated pancreatic duct 33/81 
(40.7%) 
9/29 
(31.0%) 
16/38 
(42.1%) 
7/12 
(58.3%) 
  
 
Willingness to diagnose chronic pancreatitis on the basis of symptoms and/or result of a diagnostic test in a chronic pan    
respondents were asked: ‘When do you diagnose chronic pancreatitis? Choose yes or no if you consider this as sufficient    
pancreatitis’. The reported percentages represent the percentage of respondents who answered this question on diagnos    
excluded). 
Overall: a total of gastroenterologists, internists and gastrointestinal surgeons 
a The 11 respondents other than gastroenterologists, internists and gastrointestinal surgeons are also included 
b The difference among the gastroenterologists, internists and gastrointestinal surgeons is calculated 
  
  
Medical Treatment of Pain 
  
In general, all of the 34 gastroenterologists indicated that they prescribe pancreatic 
enzymes for chronic pancreatitis, compared to 86.0% (37/43) of the internists and 
40.9% (9/22) of the gastrointestinal surgeons (P<0.001). When a patient with 
uncomplicated chronic pancreatitis presents with daily abdominal pain using only 
acetaminophen and non-steroidal anti-inflammatory agents (NSAIDs), pancreatic 
enzymes were prescribed as subsequent treatment for pain by half of the respondents: 
58.8% (20/34) of the gastroenterologists, 55.8% (24/43) of the internists and 27.3% 
(6/22) of the gastrointestinal surgeons (P=0.046). This contrasts with the experts where 
only 1 out of 7 experts (14.3%) would do so. 
A large majority of the respondents prescribed analgesics. When asked about type of 
analgesics commonly prescribed for chronic pancreatitis patients, 42.7% (47/110) 
indicated to use acetaminophen and 26.4% (29/110) used NSAIDs. Different morphine 
derivates were prescribed in a frequency ranging between 6.4 and 50.9% of the 110 
respondents: buprenorphine in 6.4% (n=7), morphine sulfate in 11.8% (n=13), fentanyl 
in 28.2% (n=31), oxycodon in 35.5% (n=39) and tramadol in 50.9% (n=56). Only few 
indicated the use of pregabalin (5/110, 4.5%) for chronic pancreatitis. Analgesics usually 
were advised on continuous basis (73/110, 66.4% of the respondents) rather than on 
demand. 
  
Treatment of Pancreatic Exocrine and Endocrine Insufficiency 
  
Fifty percent of the respondents (42/84) indicated that in case of exocrine insufficiency 
their preferred initial dose of pancreatic enzymes would be 25,000 units of lipase per 
meal and 10,000 units of lipase with snacks. A higher initial dose (50,000 units of lipase 
per meal and 25.000 units of lipase with snacks) was more frequently (although not 
significantly, P=0.701) prescribed by experts (3/7, 42.9%) compared to the respondents 
(30/84, 35.7%). Diabetes secondary to chronic pancreatitis was treated only by 
internists (38/43, 88.4%). 
  
Interventional Treatment 
  
In case of persistent pain in a chronic pancreatitis patient, respondents but also experts 
had a low threshold for interventional treatment (Table 3). All 79 respondents and 7 
experts advised to perform an intervention in case of morphological changes of the 
pancreatic duct (e.g., dilation of pancreatic duct, intraductal stones). Endoscopic 
treatment (lithotripsy and stenting of the pancreatic duct in case of stenosis) was 
preferred by internists (31/36, 86.1%) and 4 out of 7 experts (57.1%). Surgical 
treatment (pancreaticojejunostomy) was preferred by gastroenterologists (15/29, 
51.7%), gastrointestinal surgeons (8/12, 66.7%) and 2 out of 7 experts (28.6%). On the 
other hand, internists rarely referred for surgery in this case (5/36, 13.9%; P<0.001 
among gastroenterologists, gastrointestinal surgeons and internists). In case of a chronic 
pancreatitis patient with ongoing pain despite narcotics, but without dilated pancreatic 
duct or duct stones, still 22.2% (18/81) of the respondents and one out of 7 experts 
(14.3%) considered endoscopic treatment. A majority of the experts (4/7, 57.1%) 
considered surgery, as would 9.9% (8/81) of the respondents. Few respondents (13/81, 
16.0%) considered a thoracoscopic splanchnicectomy (P=0.097 among 
gastroenterologists, gastrointestinal surgeons and internists). 
  
  
Table 3. Clinical vignette: Interventional treatment in chronic pancreatitis. (We present a patient with idiopathic chronic    
abdominal pain despite analgesic use, including opioids. We ask the respondents which additional treatment they consider in tw     
and without pancreatic duct dilation). 
Which additional treatment do you consider at this 
moment? 
Overall 
(n=110) a 
Gastroenterologists 
(n=34) 
Internists 
(n=43) 
Gastroin  
surgeons  
 
 
In case of no dilated pancreatic duct (P=0.097 b): 
- Continue narcotics in a higher dose 
- Thoracoscopic splanchnicectomy 
- Enteral feeding (jejunal tube) 
- Endoscopic therapy 
- Surgical treatment 
Number of valid responses 
. 
37 (45.7%) 
13 (16.0%) 
5 (6.2%) 
18 (22.2%) 
8 (9.9%) 
81 
 
14 (48.3%) 
6 (20.7%) 
2 (6.9%) 
3 (10.3%) 
4 (13.8%) 
29 
 
15 (40.5%) 
5 (13.5%) 
2 (5.5%) 
14 (37.8%) 
1 (2.7%) 
37 
 
6 (46  
2 (15  
1 (7  
1 (7  
3 (23  
1  
 
  
 
 
  
  
 
In case of dilated pancreatic duct with intraductal 
stones (P<0.001 b): 
- Endoscopic treatment; lithotripsy and stenting of the 
pancreatic duct in case of stenosis 
- Thoracoscopic splanchnicectomy 
- Surgical treatment: pancreaticojejunostomy (Partington-
Rochelle) 
- I do not consider additional treatment at the moment 
Number of valid responses 
 
. 
50 (63.3%) 
 
1 (1.3%) 
28 (35.4%) 
 
0 
79 
 
 
13 (44.8%) 
 
1 (3.4%) 
15 (51.7%) 
 
0 
29 
 
 
31 (86.1%) 
 
0 
5 (13.9%) 
 
0 
36 
 
 
4 (33  
 
0 
8 (66  
 
0 
1  
 
 
  
 
 
  
 
 
 
Overall: a total of gastroenterologists, internists and gastrointestinal surgeons 
a The 11 respondents other than gastroenterologists, internists and gastrointestinal surgeons are also included 
b Gastroenterologists, internists and gastrointestinal surgeons were compared 
  
  
Furthermore, respondents differed in their timing of additional treatment (endoscopic or 
surgical treatment). Even in case of a chronic pancreatitis patient with a dilated 
pancreatic duct and stones, 29.6% (24/81) of the respondents only considered additional 
treatment if the patient still experiences pain (despite a maximum dose of narcotics). On 
the other hand, 70.4% (57/81) also considered additional treatment in this case if there 
is adequate pain relief (with a maximum dose of narcotics). 
  
Screening for Pancreatic Cancer 
  
Some 62.3% (37 out of the 59 respondents) recommended that patients with hereditary 
pancreatitis should enter a screening program for pancreatic adenocarcinoma. The 
majority of the respondents (n=19, 32.2%) would use EUS as screening modality, as 
would 2/7 experts (28.6%). Twenty-five percent of the respondents (n=15) would use 
CT-scanning in screening, unlike any of the 7 experts. Screening was performed annually 
or biannually, according to the respondents. Only 5.1% (n=3) of the respondents used 
MRCP for screening purposes. Screening of young relatives of hereditary pancreatitis 
patients did not yield wide support. In such cases, 84.7% (61/72) of the respondents 
(25/30, 83.3% of the gastroenterologists; 26/29, 89.7% of the internists; 9/11, 81.8% 
of the gastrointestinal surgeons; and one out of the two other respondents) would first 
refer relatives of hereditary pancreatitis patients to a department of clinical genetics for 
consultation. In order to decrease the risk of pancreatic carcinoma, a large majority of 
the respondents strongly advised cessation of alcohol consumption and cigarette 
smoking. 
  
DISCUSSION 
  
The results of our survey display the discordance between physicians when it comes to 
diagnosis, treatment, and follow-up of chronic pancreatitis. The discordance is present 
between different specialties that treat and care for chronic pancreatitis patients, but also 
among experts. This is not an unexpected result as diagnosis and treatment of these 
patients is difficult. Moreover, there is a paucity of evidence in this field and the large 
variation in answers by physicians involved in chronic pancreatitis care reflects this. We 
focused on three major components of chronic pancreatitis; diagnostics, management 
and screening. 
When it comes to laboratory test for diagnosing chronic pancreatitis, amylase was used 
frequently by internists, while gastroenterologists and experts often use fecal elastase as 
a diagnostic tool. Fecal elastase-1 test has a high predictive value for pancreatic 
insufficiency, but test lacks sensitivity for mild to moderate pancreatic exocrine 
insufficiency [12, 13]. A majority of the chronic pancreatitis experts considered 
transabdominal US as useful diagnostic imaging technique to confirm the clinical 
suspicion of chronic pancreatitis. In the recently published South African guidelines, 
transabdominal US is considered to carry limited value because of lack of sensitivity and 
specificity [12]. The Italian guidelines promote transabdominal US in confirming the 
diagnosis of advanced chronic pancreatitis, since it identifies gross abnormalities of the 
pancreas, e.g., dilatation of the pancreatic duct [11]. However, the main value of 
transabdominal US is the ability to differentiate chronic pancreatitis from other causes of 
abdominal pain. 
CT, MRCP and increasingly EUS emerge from our survey as tools to confirm the 
diagnosis, in concordance with the guidelines. The choice of diagnostic modality depends 
on the reported sensitivity and specificity, but also on the local availability and available 
skills. In addition, the diagnostic accuracy depends on the stage of disease. MRI can be 
used for the assessment of chronic pancreatitis to evaluate both parenchymal and ductal 
changes [14]. MRCP-secretin is able to detect side-branch ecstasies and can yield 
functional information of the pancreas [15]. CT has a high sensitivity and specificity and 
is frequently used as the screening test of choice. CT can show multiple aspects of 
chronic pancreatitis such as gland atrophy, dilation of the main pancreatic duct and 
pancreatic stones. However, these signs are typically restricted to advanced chronic 
pancreatitis. EUS on the other hand is increasingly being used to diagnose chronic 
pancreatitis and has proven ability to assess changes of the pancreatic parenchyma. On 
the other hand, the inter-observer variability is great, in particular in cases with so called 
“early” chronic pancreatitis. 
In the treatment of pain in uncomplicated chronic pancreatitis, respondents of this survey 
frequently use pancreatic enzymes. This is surprisingly since evidence for this strategy is 
absent. There have been several small randomized placebo-controlled trials assessing the 
ability of pancreatic enzymes to reduce pain. Two small studies using non-enteric-coated 
enzymes demonstrated a reduction in pain, while three other studies using enteric-
coated preparations showed no improvement in pain. A meta-analysis and a Cochrane 
review corroborated that enzymes are ineffective for pain [16, 17]. However, the South 
African guidelines advise a 6-week trial of high-dose pancreatic enzymes (in uncoated 
tablet form) in patients who fail to acetaminophen or NSAIDs which contrasts with the 
Italian guidelines [12]. All respondents of this survey use non-narcotic episodic analgesia 
and narcotic analgesia for pain relief. Few use pregabalin, as well as 2 of the 7 experts. 
The use of pregabalin is supported by the positive outcome of a recent randomized 
clinical trial, where it relieved chronic pancreatitis pain after 3 weeks of treatment [18]. 
In the area of interventional treatment, there are more controversies. In case of a 
chronic pancreatitis patient with pain despite narcotics but no morphological changes of 
the pancreas, 22% of the respondents and one expert still considered endoscopic 
treatment. Surprisingly, a majority of the experts (4/7; 57%) considered surgery, 
compared to 10% of the respondents. Both guidelines stipulate that interventional 
procedures should be reserved for symptomatic patients. There are no robust data that 
favor use of interventional therapy in asymptomatic patient with pancreatic duct 
dilatation. However, the Italian guidelines suggest that surgical decompression of the 
main pancreatic duct may be considered in patients with asymptomatic chronic 
pancreatitis and ductal dilation (greater than 7 mm) to prevent the progression of 
exocrine and endocrine insufficiency, but evidence is lacking [11]. 
Nonetheless, interventional procedures are either directed at addressing the 
morphological changes of the pancreatic duct system (strictures and stones), and 
inflammatory changes of the parenchyma, or by neurolysis of its nerve supply. This is 
clearly an area of uncertainty as studies in experimental obstructive pancreatitis, show 
that early drainage leads to improvement of and recovery of histological changes [19]. If 
there is an indication for an interventional treatment, responders of this survey have a 
different strategy regarding endoscopic or surgical treatment. In case of main pancreatic 
duct dilation, guidelines advice endoscopic treatment as a reasonable first option, 
because of the less invasive nature of this treatment [12]. A recent study showed that 
after 5-year follow-up, symptomatic patients with advanced chronic pancreatitis who 
underwent surgery as the initial treatment for pancreatic duct obstruction had more pain 
relief with fewer procedures, than patients who were treated endoscopically [20]. 
Moreover, almost half of the patients who were treated with endoscopy eventually 
underwent surgery. This suggests that the advice of endoscopic treatment in case of 
pancreatic duct dilation in patients with advanced disease is at odds with the available 
evidence. In case of early disease, there might be a role for endoscopic therapy but this 
requires further investigation. 
Furthermore, there are important controversies on the timing of interventional 
treatment; early in disease course or only in complicated disease. Previously, 
interventional treatment was only considered in case of pain despite narcotics. 
Nowadays, more frequently interventional treatment is advised in case of a failure of 
non-narcotic analgesia to avoid narcotic addiction. Moreover, this may lead to a better 
recovery of histological changes and pancreatic exocrine function [19]. Currently, there is 
ongoing research about timing of surgery in painful chronic pancreatitis. 
A total of some 62% of the respondents of our survey recommend screening for 
pancreatic carcinoma in hereditary pancreatitis patients with EUS or CT, annually or 
biannually. Chronic pancreatitis is known risk factor for pancreatic adenocarcinoma [21]. 
The risk is most prominent in hereditary pancreatitis. Patients with hereditary 
pancreatitis run a cumulative risks of pancreatic cancer up to 53.5% at 75 years of age 
[22]. However, routine screening of all forms of chronic pancreatitis for adenocarcinoma 
is not currently recommended [12]. Some advice screening for pancreatic 
adenocarcinoma [22]. Yet, there is no generally accepted protocol for screening chronic 
pancreatitis patients for early pancreatic cancer [23]. In recommendations for 
surveillance on pancreatic cancer in general usually no recommendations for patients on 
hereditary pancreatitis are proposed. A recent narrative review recommends yearly 
screening preferably in a referral center starting at the age of 40 [22]. MRI and CT are 
preferred as method of screening, despite lack of data. In case of absence of multiple 
calcifications, an EUS can be performed. When there is advanced hereditary pancreatitis, 
the diagnostic value of EUS is limited because fibrosis the early detection of lesion. The 
recommendations posed in the South African guidelines correspond with this review [12, 
22]. 
  
LIMITATIONS 
  
This study has limitations. There is a limited response rate. We do not know the specific 
reasons why non-responders declined participation. This may be partly due to the limited 
number of physicians involved in the care for chronic pancreatitis patients. In the 
Netherlands there are about 100 hospitals in which only a few specialists in every 
hospital treats chronic pancreatitis patients. Together they treat approximately 1,000 
new chronic pancreatitis patients every year (www.pancreatitis.nl). Thus, a large 
majority of gastroenterologists, internists and gastrointestinal surgeons sees few or even 
no chronic pancreatitis patients. Therefore, the 110 included physicians represent a 
significant part of the total group of specialist managing chronic pancreatitis in the 
Netherlands. Interestingly, a relatively large proportion of the responding physicians 
indicate that they perform interventional procedures in chronic pancreatitis (EUS-guided 
drainage of pancreatic fluid collections and surgery in chronic pancreatitis). This may 
reflect an increased interest in chronic pancreatitis by responders of the survey and 
suggest that respondents are knowledgeable of the published literature. 
In conclusion, our study documents the presence of heterogeneity in diagnostic and 
therapeutic strategies probably reflecting the lack of evidence in this field (Table 4). 
  
  
Table 4. Main controversies from this survey. 
•       Overall variation in the diagnostic and therapeutic decision-making process in clinical practice 
•       Different strategies in the diagnoses of chronic pancreatitis between internists and gastroenterologists, and experts on the oth   
•       Treatment with pancreatic enzymes frequently used in management of pain in chronic pancreatitis despite of lack of evidence 
•       A wide variation in timing of interventional procedures in uncomplicated chronic pancreatitis 
•       Different opinions on screening for pancreatic cancer in hereditary pancreatitis. 
  
  
This paper also illustrates the need for continuing education regarding the diagnosis and 
treatment of chronic pancreatitis, since wide adopted practices are not in line with 
current evidence. Considering the high number of physicians in non-academic centers 
and small hospitals, centralization of the care for chronic pancreatitis might increase 
uniformity and also improve the level of care for this complex disease. 
  
APPENDIX (supplementary file): survey of the treatment of chronic pancreatitis. 
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